Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Pneumonia 30% Improvement Relative Risk Case -19% Gönenli et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 564 patients in Turkey (May - June 2020) More cases with HCQ (not stat. sig., p=0.58) Gönenli et al., Infectious Diseases and Clinical.., doi:10.36519/idcm.2022.111 Favors HCQ Favors control
Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning of the COVID-19 Pandemic Among Physicians
Gönenli et al., Infectious Diseases and Clinical Microbiology, doi:10.36519/idcm.2022.111 (date from earlier preprint)
Gönenli et al., Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning of the COVID-19 Pandemic Among.., Infectious Diseases and Clinical Microbiology, doi:10.36519/idcm.2022.111 (date from earlier preprint)
Dec 2020   Source   PDF  
  All Studies   Meta
Small prophylaxis survey showing lower, but not statistically significant, progression to pneumonia (3 of 148 HCQ, 12 of 416 control), RR 0.70, p = 0.77. There was a higher incidence of cases with HCQ, OR 1.19, p = 0.58, which may be due to survey bias, treatment self-selection, and inconsistent regimens. Improvement on severity may be related to the higher HCQ concentration in lung tissue, and also reflect that binary PCR does not distinguish replication-competence. Details of the pneumonia numbers for treatment/control are from the author, it's unclear why the lower progression to pneumonia was not reported in the paper.
risk of pneumonia, 29.7% lower, RR 0.70, p = 0.77, treatment 3 of 148 (2.0%), control 12 of 416 (2.9%), NNT 117.
risk of case, 18.9% higher, RR 1.19, p = 0.58, treatment 8 of 148 (5.4%), control 20 of 416 (4.8%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gönenli et al., 16 Dec 2020, retrospective, Turkey, peer-reviewed, survey, mean age 36.0, 9 authors, study period 14 May, 2020 - 13 June, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: ORIGINAL ARTICLE Infect Dis Clin Microbiol 2022; 4(4): 236-43 Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning of the COVID-19 Pandemic Among Physicians Mehmet Gökhan Gönenli1 , İlker Kayı2 , Nilüfer Alpay Kanıtez1 , Tuba Baydaş3 , Murat Köse4 Nalbantoğlu1 , Miraç Vural Keskinler5 , Timur Selçuk Akpınar4 , Önder Ergönül6,7 , Emine Ayça ¹ Department of Internal Medicine, Koç University Hospital, İstanbul, Turkey 2 Department of Public Health, Koç University Hospital, İstanbul, Turkey 3 Department of Internal Medicine, Bezmialem University Hospital, İstanbul, Turkey 4 Department of Internal Medicine, İstanbul University İstanbul School of Medicine, İstanbul, Turkey 5 Department of Internal Medicine, Istanbul Medeniyet University, Göztepe Education and Research Hospital, İstanbul, Turkey 6 Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, Istanbul, Turkey 7 Koç University İşbank Center for Infectious Diseases, Istanbul, Turkey ABSTRACT Objective: Throughout the pandemic, physicians working at the frontlines have embarked on various quests to protect themselves, and many physicians preferred using hydroxychloroquine (HQN) as a prophylactic agent. This study aimed to investigate the reasons leading physicians to use HQN and its effects on them. Materials and Methods: This study is cross-sectional with a target population of physicians working in pandemic hospitals in İstanbul, Turkey. We invited participants from seven hospitals via email between May 14 and June 13, 2020. An online questionnaire, including 57 questions, was sent to physicians. Results: A total of 148 (26%) physicians out of 564 participants had used hydroxychloroquine for prevention. Older physicians and those with a history of exposure to COVID-19 patients without protection used prophylactic HQN more frequently. The use of HQN did not differ statistically in terms of being infected among the exposed physicians (p=0.52). Nineteen (13%) physicians using HQN developed side effects related to the drug. Diarrhea and nausea were the most common. Conclusion: Prophylactic HQN use was more common among physicians older than 40 years and with higher exposure rates to a COVID-19 patient without protection. The physicians working on the front line had the highest rate of infection. HQN was not effective in the prophylaxis of COVID-19 among the exposed physicians. Keywords: COVID-19, hydroxychloroquine, prophylaxis, physicians Corresponding Author: İlker Kayı E-mail: Received: December 6, 2021 Accepted: November 22, 2022 Published: December 21, 2022 Suggested citation: Gönenli MG, Kayı İ, Alpay Kanıtez N, Baydaş T, Köse M, Nalbantoğlu EA, et al. Analysis of the prophylactic use of hydroxychloroquine at the beginning of the COVID-19 pandemic among physicians. Infect Dis Clin Microbiol. 2022;4:236-43. DOI: 10.36519/idcm.2022.111 This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. 236 HQN use among physicians during the pandemic
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop